Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients under evaluation for a suspected hematological malignancy or with a diagnosis of hematological malignancy (acute and chronic leukemias, lymphomas, myeloma, and others) will be included in the study. 2. Patients who are planned for or receiving chemotherapy / immunotherapy / targeted therapy in the OPD, ward, daycare and ICU will be eligible.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who plan to continue on full intensity therapy- This will be the percentage of patients who are willing to go ahead with the full intensity therapy in the current scenario.Timepoint: 6 months or till the end of pandemic | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in preferences- This will be calculated as the difference in the risk levels at which the patient and physician opt for full-intensity treatment.Timepoint: 6 months or till the end of pandemic;Factors that lead to treatment discontinuation- In patients who opt for discontinuation or reduction of treatment, the various factors such as logistic factors, fear of complications of corona, type of disease and intent of treatment will be analyzed.Timepoint: 6 months or till the end of pandemic;Level of perceived risk at which patient will opt for treatment discontinuation/dose reduction- The mean percentage of risk at which patient opts for treatment discontinuation/dose reduction will be calculated. This will be calculated separately for A. Risk of COVID-19 related complications. B. Risk of relapse over and above the baseline risk. The risk categories will be presented as a scale.Timepoint: 6 months or till the end of pandemic;Treatment preferences in different scenarios- Patients will be presented various scenarios of the risk of COVID-19 related complications and they will be asked at what level of risk of relapse will they opt for therapy.Timepoint: 6 months or till the end of pandemic | — |
Countries
India
Contacts
Public ContactDr Avinash Bonda
Tata Memorial Center
Outcome results
None listed